A new strategy for chemotherapy-based therapy of various types of cancer is based on the design of PROTAC molecules, which are hybrid chemical structures aiming to degrade over-expressed proteins via ubiquitination pathways in cancer cells. They consist of a warhead that binds to an overexpressed protein marked for degradation, a linker and a compound that binds to an E3 ligase enzyme. A panel of recently synthesized combretastatin derivatives with attractive pharmacological properties have been investigated in this project. They were docked to the main β tubulin isotypes and their binding affinities were compared. The ADMET properties of these compounds were analyzed and used to search for a correlation with the biological activity of these derivatives, which were previously tested in vitro to assess their cytotoxicity.